StockNews.com Upgrades Marinus Pharmaceuticals (NASDAQ:MRNS) to Hold

StockNews.com upgraded shares of Marinus Pharmaceuticals (NASDAQ:MRNS) from a sell rating to a hold rating in a report issued on Monday.

A number of other equities analysts have also recently commented on MRNS. HC Wainwright reaffirmed a buy rating and set a $11.00 price target on shares of Marinus Pharmaceuticals in a research note on Wednesday, August 14th. Truist Financial restated a buy rating and set a $10.00 target price on shares of Marinus Pharmaceuticals in a research report on Tuesday, June 18th. Cantor Fitzgerald reaffirmed an overweight rating and set a $13.00 target price on shares of Marinus Pharmaceuticals in a research note on Monday. Finally, LADENBURG THALM/SH SH lowered Marinus Pharmaceuticals from a buy rating to a neutral rating in a research note on Wednesday, August 14th. Five research analysts have rated the stock with a hold rating and three have given a buy rating to the company. Based on data from MarketBeat, the stock presently has an average rating of Hold and a consensus target price of $10.25.

Marinus Pharmaceuticals Stock Performance

Shares of MRNS stock opened at $1.39 on Monday. The company has a market cap of $76.36 million, a PE ratio of -0.53 and a beta of 1.13. Marinus Pharmaceuticals has a 1 year low of $1.05 and a 1 year high of $11.26. The stock’s 50 day simple moving average is $1.34 and its two-hundred day simple moving average is $3.21. The company has a debt-to-equity ratio of 5.68, a current ratio of 2.28 and a quick ratio of 2.15.

Marinus Pharmaceuticals (NASDAQ:MRNS) last released its quarterly earnings results on Tuesday, August 13th. The biopharmaceutical company reported ($0.60) earnings per share for the quarter, missing the consensus estimate of ($0.59) by ($0.01). The company had revenue of $8.06 million for the quarter, compared to analysts’ expectations of $9.05 million. Marinus Pharmaceuticals had a negative net margin of 493.14% and a negative return on equity of 7,831.35%. During the same quarter in the previous year, the company posted ($0.61) EPS. Research analysts predict that Marinus Pharmaceuticals will post -1.88 earnings per share for the current year.

Institutional Trading of Marinus Pharmaceuticals

A number of large investors have recently modified their holdings of MRNS. Point72 DIFC Ltd bought a new stake in Marinus Pharmaceuticals during the 2nd quarter valued at $28,000. SG Americas Securities LLC purchased a new position in shares of Marinus Pharmaceuticals during the second quarter valued at $34,000. AQR Capital Management LLC lifted its stake in Marinus Pharmaceuticals by 70.3% in the second quarter. AQR Capital Management LLC now owns 31,333 shares of the biopharmaceutical company’s stock worth $37,000 after acquiring an additional 12,934 shares during the period. Jacobs Levy Equity Management Inc. bought a new position in Marinus Pharmaceuticals during the 1st quarter worth about $384,000. Finally, Trexquant Investment LP bought a new position in Marinus Pharmaceuticals during the 4th quarter worth about $553,000. Hedge funds and other institutional investors own 98.80% of the company’s stock.

Marinus Pharmaceuticals Company Profile

Marinus Pharmaceuticals, Inc, a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings.